Table 4

Predictors of persistence of protective antibody levels for both 23F and 6B 1.5 years after pneumococcal vaccination by using 7-valent conjugate vaccine in patients with rheumatoid arthritis and spondyloarthropathy

Univariate logistic regression analysis


RA

P value; OR (95% CI)

Spondyloarthropathy

P value; OR, 95% CI


Age ≥65 years (yes/no)

P = 0.144; OR 0.59 (0.29-1.2)

P = 0.012; OR 0.24 (0.08-0.74)


Gender (male/female)

P = 0.727; OR 0.86 (0.37-2.0)

P = 0.120; OR 1.72 (0.07-3.40)


Disease duration (years)

P = 0.011; OR 0.96 (0.93-0.99)

P = 0.895; OR 1.0 (0.97-1.03)


DAS at vaccination (0-6.5)

P = 0.684; OR 0.94 (0.68-1.28)

P = 0.014; OR 0.70 (0.51-0.93)


HAQ at vaccination (0-3)

P = 0.020; OR 0.54 (0.32-0.91)

P = 0.043; OR 0.48 (0.24-0.98)


Ongoing MTX (yes/no)

P = 0.807; OR 0.92 (0.45-1.9)

P = 0.078; OR 0.53 (0.26-1.07)


Ongoing anti-TNF (yes/no)

P = 0.066; OR 0.53 (0.27-1.04)

P = 0.086; OR 0.51 (0.24-1.1)


Ongoing prednisolone (yes/no)

P = 0.259; OR 0.64 (0.29-1.40)

P = 0.390; OR 0.62 (0.21-1.84)


Positive antibody response for both 6B and 23F at 4 to 6 weeks

P = 0.180; OR 1.70 (0.78-3.71)

P = 0.630; OR 1.19 (0.59-2.36)


Protective prevaccination antibody levels for both 23F and 6B (yes/no)

P < 0.001; OR 12.1 (5.38-27.4)

P < 001; OR 14.6 (5.83-36.4)


Multivariate logistic regression analysis


Age ≥65 years (yes/no)

P = 0.188; OR 0.59 (0.26-1.30)

P = 0.017; OR 0.22 (0.06-0.76)


Gender (male/female)

P = 0.480; OR 0.70 (0.26-1.88)

P = 0.637; OR 1.24 (0.51-2.97)


Disease duration (years)

P = 0.214; OR 0.98 (0.94-1.01)

P = 0.873; OR 1.01 (0.97-1.04)


HAQ at vaccination (0-3)

P = 0.139; OR 0.62 (0.32-1.17)

P = 0.291; OR 0.63 (0.27-1.49)


Ongoing MTX (yes/no)

P = 0.065; OR 0.39 (0.14-1.06)

P = 0.882; OR 0.94 (0.39-2.27)


Ongoing anti-TNF (yes/no)

P = 0.024; OR 0.34 (0.13-0.87)

P = 0.195; OR 0.54 (0.21-1.37)


Positive antibody response for both 6B and 23F at 4-6 weeks

P = 0.388; OR 1.45 (0.62-3.40)

P = 0.916; OR 1.04 (0.49-2.23)


Adjusted for age older than 65 years, gender, disease duration, HAQ, ongoing MTX, ongoing anti-TNF, and positive antibody response for both serotypes tested. MTX, methotrexate; HAQ, health-assessment questionnaire.

Crnkic Kapetanovic et al. Arthritis Research & Therapy 2013 15:R1   doi:10.1186/ar4127

Open Data